Myora

Quick links to important sections

Myora

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Myora

Quick Facts

Property Description
Active Ingredients Chlorzoxazone, Paracetamol (Acetaminophen)
Form Oral Tablet
Pharmacological Class Central Acting Skeletal Muscle Relaxant, Analgesic, Antipyretic
General Purpose Relief of pain associated with muscle spasm
Origin Synthetic Compound

Myora is defined as a fixed-dose combination product designed to provide simultaneous relief from discomfort associated with painful muscle stiffness and spasms. This prescription-only medicine is a synthetic compound formulated as a single oral tablet and falls under the pharmacological classification of a combined central acting skeletal muscle relaxant and a non-opioid analgesic / antipyretic.


Composition and Dual Active Ingredients

Myora contains two distinct active ingredients: Chlorzoxazone and Paracetamol. Chlorzoxazone functions as the skeletal muscle relaxant component, which acts to relieve skeletal muscle rigidity and discomfort. This ingredient helps by relaxing the muscles during acute discomfort. The second ingredient is Paracetamol, also known as Acetaminophen, which provides pain relief and fever reduction. This component acts to alleviate general pain symptoms and lower high body temperature.

The final oral formulation combines these active compounds with solid oral excipients into a tablet, ensuring that the two therapeutic actions are delivered concurrently.


General Therapeutic Purpose

Myora's overall purpose is to provide targeted relief by managing the pain and spasm components of acute musculoskeletal discomfort. A typical use scenario involves the short-term relief of pain following muscle strains or injury where involuntary muscle contraction is a primary issue. Chlorzoxazone acts on the central nervous system (CNS) to reduce the involuntary signals that cause muscle spasm and rigidity, promoting skeletal muscle relaxation. The Paracetamol component provides supplementary pain relief. This combination focuses on providing relief from musculoskeletal pain associated with muscle tightening.

Regulatory References

  1. Chlorzoxazone Monograph - DailyMed
  2. Acetaminophen Drug Information - MedlinePlus

What side effects are possible with Myora?

Possible Side Effects and Safety Information

The safety profile of Myora is based on official government regulatory documents that categorize documented adverse reactions and establish necessary safety limitations.

Reproductive Safety Warnings and Restrictions

Regulatory agencies classify Myora as a teratogen because exposure during pregnancy can cause severe and permanent birth defects, including abnormalities of the ear, eye, face, heart, fingers, and nervous system, and a high risk of miscarriage. These risks necessitate strict safety requirements:

  • For females of childbearing potential: A negative pregnancy test is required before starting treatment, and the consistent use of effective contraception is mandatory during treatment and for six weeks after the last dose.
  • For male patients: Reliable contraception must be used with a female partner during treatment and for 90 days after the last dose. Men must not donate sperm during this 90-day period.
  • Blood donation restriction: All patients are prohibited from donating blood during treatment and for six weeks after stopping the medicine.

Other Clinically Significant Adverse Reactions

The medicine's immunosuppressive effects lead to other documented safety concerns across various organ systems. The profile includes an increased risk of infections, which may be serious (e.g., sepsis), and a potential for malignancies (cancers), such as lymphomas and skin cancer.

Adverse reactions are officially categorized by frequency in regulatory labels. Very common adverse reactions (affecting more than 1 in 10 patients) often include specific infections, and gastrointestinal issues.

Overdose and Emergency Response

Myora Overdose and When to Seek Help

The following information is based strictly on documentation found in official government regulatory resources, such as the prescribing information and public assessment reports.

Overdose Presentations and Emergency Action

Classification Official Regulatory Statement
Documented Manifestations Symptoms following overexposure are officially documented and may include specific physiological effects such as reduced level of consciousness, respiratory depression, severe hypokalaemia, or specific organ toxicities (e.g., renal tubular acidosis or liver damage).
Life-Threatening Risks Overdose is classified as having the potential to be life-threatening or fatal due to complications such as acute renal failure, coma, or circulatory depression.
Emergency Response Required Immediate medical attention must be sought in all cases of suspected overdose. The official instruction is to contact a poison control center or emergency medical services without delay.

Management and Monitoring

Specific management procedures are outlined in regulatory documents to address overexposure. These procedures typically include general supportive measures to maintain vital functions (e.g., maintaining an airway and supporting ventilation). Depending on the substance, the documents may state that enhanced drug elimination procedures, such as dialysis, may be considered if documented as effective. If a specific antidote exists, its recommended use is described; otherwise, the labeling explicitly states that no specific antidote is available. Prolonged monitoring is often specified to watch for delayed or evolving toxicity.

Population-Specific Notes

For certain substances, accidental ingestion of even a single dose by children is documented as a risk for fatal poisoning, emphasizing the need for extreme caution and immediate emergency response in paediatric cases.

Therapeutic Uses of Myora

Myora: Main Uses

Quick Facts
Therapeutic Domain Prophylaxis of transplant rejection
Primary Use Supports the body's acceptance of a new organ
Supported Transplants Kidney, Heart, and Liver

Myora is a prescription medication utilized in adult and pediatric patients (3 months of age and older) who have received an allogeneic solid organ transplant. Its principal function is as an adjunctive treatment, administered in combination with other immunosuppressive agents such as corticosteroids and cyclosporine.

Therapeutic Role

The primary use of Myora is for the prophylaxis of organ rejection. This means the medication helps to support the body’s acceptance of the new organ by addressing the natural immune response that may otherwise lead to the rejection of the transplanted tissue. This therapeutic application is specifically indicated for individuals receiving a kidney, heart, or liver transplant.

The initiation of Myora therapy occurs as early as possible following the transplant procedure.

Eligibility and Restrictions for Use

Myora (mycophenolate mofetil) is approved for use in adult and pediatric patients aged 3 months and older who are recipients of allogeneic kidney, heart, or liver transplants. Its use is limited to these specific populations.

Populations Who Must Not Use Myora (Contraindications)

Official regulatory documents strictly prohibit the use of Myora in several patient groups:

  • Hypersensitivity: Individuals with a documented allergic reaction to mycophenolate mofetil, mycophenolic acid, or any other component of the medicine.
  • Pregnancy and Lactation: Women who are pregnant or who are breastfeeding must not use this medicine.
  • Females of Reproductive Potential: Use is strictly prohibited for women of childbearing potential who are not using highly effective contraception and who do not have a negative pregnancy test prior to starting treatment.
  • Genetic Conditions: Patients diagnosed with rare hereditary deficiencies of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT), such as Lesch-Nyhan syndrome or Kelley-Seegmiller syndrome, are excluded.

Conditions Requiring Special Consideration

The medicine is generally not recommended or requires caution for patients with severe chronic renal impairment (kidney disease) or those with active serious digestive system disease.

What should I know about interactions with other medicines?

Myora Interactions with other medicines and products

Interaction Scope

The official regulatory profile for Myora is structured by the interaction risks associated with its dual components. Co-administration is formally restricted with other acetaminophen-containing products to prevent exceeding the maximum daily dosage and to avoid the resulting risk of severe liver toxicity.

Pharmacodynamic and Substance Interactions

Due to the muscle relaxant component, a pharmacodynamic interaction exists with alcohol and other Central Nervous System (CNS) Depressants (e.g., sedatives, narcotics, tranquilizers). This combination may result in additive CNS effects, as specified in official labeling. Furthermore, the regular daily use of the Acetaminophen component with Warfarin and other Coumarins is documented to enhance the anticoagulant effect, which increases the risk of bleeding.

Pharmacokinetic and Timing Rules

Pharmacokinetic alterations are also documented. Metoclopramide and Domperidone are known to increase the absorption rate of the Acetaminophen component. Conversely, Colestyramine reduces its absorption speed; therefore, regulatory documents state that Colestyramine should not be given within one hour if a maximal analgesic effect is required. Substances that induce the CYP2E1 enzyme may also increase the risk of hepatotoxicity.

Official documents note that the severity of toxicity and interactions is greater in populations with severe hepatic impairment and in chronic alcohol abusers.

Mechanism of Action

The drug Myora is an inhibitor of the mechanistic Target of Rapamycin Complex 1 (mTORC1). Myora acts by forming a complex with the intracellular protein FKBP12 (FK506-binding protein 12). This resultant Myora-FKBP12 complex then non-covalently associates with and allosterically inhibits the catalytic activity of the mTOR serine-threonine kinase within the mTORC1 multiprotein complex.


Molecular and Intracellular Pathways

Inhibition of mTORC1 kinase activity prevents the phosphorylation of its direct downstream substrates, primarily the eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and the p70 ribosomal S6 kinase 1 (S6K1). The decreased phosphorylation of 4E-BP1 prevents its dissociation from the eukaryotic initiation factor 4E (eIF4E), which suppresses the assembly of the eIF4F complex, thus inhibiting cap-dependent protein translation. The decreased phosphorylation and activation of S6K1 further modulates translation and reduces the production of ribosomal proteins. The downstream cascade also involves the suppression of lipid and nucleotide biosynthesis and the simultaneous induction of autophagy (a catabolic process).


System-Level Physiological Consequences

The cumulative intracellular effects—namely the suppression of protein synthesis, lipid biosynthesis, and the promotion of catabolism—result in a modulation of cellular growth, proliferation, and survival pathways, leading to a generalized attenuation of activated T-lymphocyte function and cell-cycle progression in responsive tissues.

Dosage and Administration Information

The administration of Myora, a fixed-dose combination oral tablet containing Chlorzoxazone and Paracetamol, follows structured guidelines regarding its route, dosing, and schedule, as an adjunct to rest and physical measures.

Administration Guidelines

Administration Scope Description
Route Administered by the oral route as a tablet.
Standard Dosing The Chlorzoxazone component is typically started at 250 mg to 500 mg per dose. The dose may be increased to a maximum of 750 mg per dose if the initial response is inadequate.
Frequency The total daily dose is taken in divided doses three or four times per day.
Duration and Reduction Use is generally designated for short-term management; as improvement occurs, the dosage can usually be reduced.
Timing with Meals The tablet may be administered with food or milk if its intake causes gastrointestinal upset.

Population-Specific Use Rules

Age Group/Condition Dosing Rule
Pediatric Dosing The Chlorzoxazone component is typically dosed based on weight or body surface area (BSA), such as 20 mg/kg/day or 600 mg/m^2 /day, divided three or four times daily.
Liver Impairment Avoidance of use is a significant consideration due to the drug's metabolism.
Missed Dose If a dose is missed and it is not almost time for the next dose, the missed dose should be taken as soon as possible, but double doses should be avoided.

The oral administration of Myora involves a structured approach that establishes maximum daily limits for both active ingredients and links dose duration to the achievement of improvement.

Recent Clinical Evidence

Research evidence / Overview of Studies for Myora


Evidence for Use in Acute Painful Muscle Spasm

Myora is a combination drug that was the focus of research examining populations with acute, painful musculoskeletal conditions, such as sudden, non-specific lower back pain where muscle spasm is a contributing factor. The primary research exploring this is based on short-term randomized controlled trials (RCTs). These studies typically compare Myora's active components against a placebo or against other common pain relievers and muscle relaxants.

Researchers monitored patient-reported outcomes describing physical discomfort, mainly through validated scales that measure pain intensity. They also used objective clinical tests to assess the severity of muscle stiffness. The findings describe patterns observed in the studies, typically over limited durations, often no more than one week. Data show patterns related to pain intensity outcomes.


Duration of Evidence: Short-Term vs. Extended Follow-Up

Most of the research on Myora, and the class of muscle relaxants it belongs to, involves studies with limited follow-up durations. Research focusing on episodes where symptoms become more noticeable was typically conducted over periods of seven days or less. This design allows researchers to gather detailed data on the initial acute response.

Long-term effects are not fully established, as there is limited information for long-term outcomes that persist beyond four weeks. Research provides limited insight into the sustained impact on functional recovery or whether it may influence the frequency of future symptom flare-ups over many months. The current data are best understood as reflecting evidence derived from settings with varying symptom burdens.


Research Consistency and Scientific Gaps

The available evidence primarily reflects results from the adult populations studied in the main clinical trials. Data for certain groups remain insufficient, meaning the results apply most directly to the populations that were included in the research. Specifically, there are few dedicated studies exploring the use of Myora in pediatric patients or older adult populations.

The overall evidence quality varies across studies, with some older trials having sample sizes that were modest. A primary research limitation is that comparative evidence is lacking for all possible alternatives; researchers have not definitively studied whether this specific fixed-dose combination was associated with measurable differences compared to all other monotherapies or combinations of muscle relaxants. Ultimately, research highlights what is known—and what is still uncertain, particularly regarding long-term effects and outcomes in vulnerable patient subgroups.

Key Studies & References

  1. Acetaminophen Drug Information - National Library of Medicine (NLM)

Frequently Asked Questions (FAQ)

Common questions about Myora (FAQ)


Q: How quickly can someone expect Myora to start working?

A: Studies on the components of Myora indicate they are rapidly absorbed after taking the oral tablet. The pain-relieving ingredient (Paracetamol/Acetaminophen) has been studied to reach peak levels in the bloodstream within a range of about 10 minutes to one hour after administration. The muscle relaxant ingredient (Chlorzoxazone) usually reaches its peak concentration within one to two hours.


Q: Is Myora considered a controlled substance?

A: According to the U.S. Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA), neither Chlorzoxazone nor Paracetamol are classified as federally scheduled controlled substances. The current classification of these components indicates a low potential for abuse or dependence, according to the DEA.


Q: Are there any known serious interactions with common over-the-counter medications?

A: Official drug information emphasizes a formal restriction on taking Myora with other over-the-counter products that contain Acetaminophen (Paracetamol). This restriction prevents severe liver toxicity that can result from exceeding the safe daily limit of Acetaminophen. Official guidelines emphasize that patients should review all over-the-counter medicines with a healthcare professional.


Q: Can Myora be taken with vitamins or supplements?

A: Official regulatory guidelines recommend that patients discuss the use of this medicine alongside all prescription, non-prescription, vitamin, and herbal products with a healthcare professional. This review is generally conducted to help identify any potential interactions that may affect the medicine’s safety or effectiveness.


Q: Are there known food or drink restrictions while taking Myora?

A: Official labeling specifies a pharmacodynamic interaction with alcohol and other Central Nervous System (CNS) depressants, which may result in additive sedative effects. Furthermore, chronic alcohol abuse increases the risk of serious liver damage from the Paracetamol component.


Q: Do older adults typically use Myora differently?

A: Studies and official warnings indicate that older adults (65 years or older) may be at a greater risk for certain side effects such as increased drowsiness, confusion, and a higher risk of falling. Therefore, regulatory warnings describe that the use of this drug in older adults is generally approached with caution.


Q: Is it normal to feel a change in mood when starting Myora?

A: The official documentation for the muscle relaxant component notes that some patients may occasionally experience general discomfort or illness (malaise), lightheadedness, or drowsiness. However, a specific change in mood is not explicitly listed as a common or rare adverse reaction in regulatory safety labels.


Q: What are the official warnings about Myora?

A: Major warnings described in regulatory documents primarily revolve around the risk of serious, potentially fatal liver injury (hepatocellular toxicity) and significant Central Nervous System (CNS) depressant effects. Regulatory documents state that symptoms like jaundice, fever, rash, or dark urine should be reported to a healthcare professional immediately. The drug also requires caution due to its effects during pregnancy.


Q: How does the body typically process Myora?

A: Official pharmacological information indicates that both active ingredients are absorbed quickly and completely by the body. They are rapidly metabolized, primarily in the liver, into other compounds. These resultant compounds are then mostly eliminated from the body through the urine.


Q: What research exists about Myora's use in children?

A: While the Chlorzoxazone component alone has established weight-based dosing guidelines for pediatric use, the official drug label for this specific combination product (Myora) may contain safety restrictions. Regulatory documents state that the general safety and effectiveness of this combination drug have not been definitively established for most children.


Q: What should I do if I think I'm having a side effect?

A: Official guidance emphasizes that if symptoms of serious side effects (such as signs of liver problems, allergic reactions, or stomach bleeding) are experienced, the medicine should be discontinued and emergency medical help should be sought immediately. Patients also have the option to officially report side effects to the Food and Drug Administration (FDA).


Q: Is it true that Myora can affect heart rate?

A: A fast heartbeat is listed in some official adverse reaction reports as a less common side effect. Although rare, a change in heart rate is a symptom that, if experienced, would typically require medical attention.


Q: Are there specific symptoms that require a call to a doctor while using Myora?

A: Yes. Official warnings advise that patients must stop using the medicine and seek a doctor's attention immediately if they experience any signs of liver dysfunction, which include jaundice (yellowing of the skin/eyes), dark urine, fever, rash, or unusual tiredness. These symptoms are described as warranting urgent medical review.


Q: What happens if I accidentally take too much Myora?

A: Official regulatory warnings state that an overdose can lead to severe symptoms such as extreme drowsiness, nausea, vomiting, muscle weakness, or shallow breathing. Overdose is specifically associated with the risk of severe liver damage and requires immediate emergency medical attention.


Q: How long do the effects of Myora usually last after taking it?

A: Official pharmacological data indicates that the pain-relieving effects of the Paracetamol component generally last for 3 to 5 hours after a single dose. The body rapidly eliminates both Chlorzoxazone and Paracetamol from the blood, with both components having an elimination half-life of 1 to 3 hours.


Q: What is the purpose of the boxed warning, if one exists, for Myora?

A: Because the product contains Acetaminophen (Paracetamol), regulatory bodies have mandated that the official label carries a Boxed Warning (often called a 'Black Box Warning'). This is the strongest warning type and highlights the significant risk of severe liver injury (hepatotoxicity) and serious allergic reactions associated with the Acetaminophen component.


Q: Can Myora affect birth control pills?

A: Studies suggest that the Paracetamol (Acetaminophen) component, when taken regularly, may potentially increase the plasma concentrations of the estrogen component found in some oral contraceptive pills. This interaction is noted in regulatory sources as a possibility for women who are consistently taking Paracetamol.


Q: What are the less common, but officially listed, side effects of Myora?

A: Official regulatory documents list several less common adverse reactions, which include allergic-type skin reactions such as rashes and swelling, as well as gastrointestinal bleeding. Other reported reactions include the appearance of small bruises (petechiae or ecchymoses). Discolored urine may also occur, but it is generally considered harmless.


Q: Can Myora cause problems with driving or operating machinery?

A: Yes. Due to the potential to cause drowsiness, dizziness, or lightheadedness, official warnings recommend avoiding driving a car or operating machinery until the patient knows how the medication affects them.


Q: What are the official sources to check for updates on Myora safety?

A: Official and up-to-date safety information can be accessed directly from government authorities and their resources. These include the U.S. Food and Drug Administration (FDA) and its drug information resource, DailyMed, or the National Institutes of Health (NIH) MedlinePlus.

How should Myora be stored and disposed of?

The official regulatory profile for Myora defines specific conditions for storage, handling, and disposal.

Official Storage and Handling

Myora tablets must be kept at controlled room temperature (e.g., 20 C to 25 C). The product must be stored in its original container, which should be kept tightly closed, and protected from light and moisture to maintain stability. Tablets must not be crushed or opened, and direct contact with the powder should be avoided. The product is also explicitly labeled with the instruction “Do not refrigerate” and “Do not freeze.” For child safety, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired Myora product must follow official local regulations for pharmaceutical waste. It is specifically stated that the medicine must not be disposed of via wastewater (i.e., flushing) or general household trash. The preferred method is returning the product to an official drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Myora found in:

A-Z Index: